IDO1 and diabetic retinopathy: Collectively, these results support that short-term systemic PAD4i treatment showed benefit by reducing retinal NETosis, slowing progression of diabetic retinopathy, decreasing intestinal inflammation as determined by IDO expression, lowering systemic neutrophil activation and decreasing permeability of the small intestine.